B+
Bull case
25%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
PAHC
Phibro Animal HealthCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Record fiscal 2026 sales, 39% adjusted-EBITDA growth, margin expansion and broad legacy-business momentum show that operational improvements are producing measurable results. Sustained Animal Health growth and successful manufacturing consolidation could support further upside.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Closing Chicago Heights and transferring production could create transition costs, supply disruption or delayed efficiency benefits.
Momentum
89
Value
56
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $35.00 · Bull $44.00 · Bear $27.00Analysis 2026-09-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $47.00
Why
Momentum89 · Δ7d +3.3
Value56 · Δ7d -0.0
Sentiment44 · Δ7d -1.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Closing Chicago Heights and transferring production could create transition costs, supply disruption or delayed efficiency benefits.
- • Fiscal 2027 sales and adjusted-EBITDA guidance imply substantial growth deceleration from fiscal 2026.
- • Fiscal 2027 guidance points to low-single-digit sales and adjusted-EBITDA growth after an unusually strong fiscal 2026, creating risk that transformation benefits and acquisition-driven momentum are cresting.
Catalyst clock
2026-08-26
Fiscal 2026 results confirmed stronger margins and portfolio execution
Lead driver: Value · See fundamentals
Momentum
89
8% active weight
Current posture
7d trendFlat
Δ7d
+3.3
Δ21d
+34.0
Value
56
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.9
Sentiment
44
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.2
Δ21d
-12.0
Why this grade
Composite grade C. Momentum 88.5 / Value 55.8 / Sentiment 43.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$1.58B
Beta
0.79
Shares Out
40.6M
P/E (TTM)
23.1
P/S (TTM)
1.11
P/FCF (TTM)
104.84
Rev YoY
+10.3%
EPS YoY
+14.1%
Gross Margin
+32.3%
Op Margin
+12.3%
Net Debt
$684.51M
Current Ratio
3.17
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data